Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNxt SolutionsSTU:BXT +3.78%25 OCF Yield % is -10.95 as of Aug. 14, 2026. GuruFocus rates STU:BXT with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, BioNxt Solutions ranks worse than 87.26% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BioNxt Solutions OCF Yield % Related Terms
BioNxt Solutions OCF Yield % Historical Data
* Premium members only.
The historical data trend for BioNxt Solutions's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioNxt Solutions's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNxt Solutions OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioNxt Solutions's OCF Yield % distribution charts can be found below:
* The bar in red indicates where BioNxt Solutions's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNxt Solutions (STU:BXT) has a OCF Yield % of -10.95 as of Aug. 14, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BioNxt Solutions and its competitors. According to the industry distribution chart, BioNxt Solutions ranks #877 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is BioNxt Solutions' OCF Yield % too high?
BioNxt Solutions' current OCF Yield % is -10.95. Based on the distribution chart, BioNxt Solutions ranks #877 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioNxt Solutions has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does BioNxt Solutions' OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioNxt Solutions ranks #877 out of 1005 companies for OCF Yield %. This places BioNxt Solutions in the lower half of its industry. The industry median OCF Yield % is 3.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.34, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BioNxt Solutions and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNxt Solutions's current OCF Yield % is -10.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNxt Solutions stock overvalued right now?
BioNxt Solutions (STU:BXT) has a current OCF Yield % of -10.95. The current OCF Yield % is -10.95. BioNxt Solutions' overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BioNxt Solutions (STU:BXT), the current OCF Yield % is -10.95 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioNxt Solutions Inc is is a bioscience innovator focused on next-generation drug delivery systems. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, focused on European markets. The company is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes. Its pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, BNT24004. Its geographic areas are Austria, Germany, Switzerland regions.
25GF Score
Get the complete analysis for STU:BXT
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BXT has been successfully added to your 
